NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Do institutionals and insiders have more ownership in NAMS or BPMC?

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media favor NAMS or BPMC?

In the previous week, Blueprint Medicines had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Blueprint Medicines and 1 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.54 beat Blueprint Medicines' score of 0.84 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Blueprint Medicines	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, NAMS or BPMC?

NewAmsterdam Pharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Is NAMS or BPMC more profitable?

Blueprint Medicines has a net margin of -27.70% compared to NewAmsterdam Pharma's net margin of -397.45%. NewAmsterdam Pharma's return on equity of -37.34% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-397.45%	-37.34%	-33.45%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Do analysts prefer NAMS or BPMC?

NewAmsterdam Pharma presently has a consensus target price of $42.89, suggesting a potential upside of 116.12%. Blueprint Medicines has a consensus target price of $128.06, suggesting a potential downside of 0.16%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Which has stronger valuation and earnings, NAMS or BPMC?

Blueprint Medicines has higher revenue and earnings than NewAmsterdam Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$45.56M	48.90	-$241.60M	-$1.88	-10.56
Blueprint Medicines	$508.82M	16.28	-$67.09M	-$2.47	-51.93

Summary

NewAmsterdam Pharma beats Blueprint Medicines on 10 of the 17 factors compared between the two stocks.